Mirvetuximab soravtansine is a recently developed antibody drug conjugate for ovarian cancer treatment consisting of a humanised monoclonal folate receptor alpha (FR-α) antibody, which is linked via a cleavable disulphide bond to maytansinoid DM4, a synthetic derivative of the highly potent cytotoxic agent maytansine. The gene discussed is FOLR1; the disease is ovarian carcinoma.